FDA approves NDA to determine safety, efficacy of psilocybin for OCD treatment

The FDA has approved an investigational new drug application from Ceruvia Lifesciences to conduct a phase 2 clinical trial to determine the safety and efficacy of synthetic psilocybin for the treatment of obsessive-compulsive disorder.
“With positive preliminary results from a Ceruvia-funded pilot phase 2 study taking place at Yale School of Medicine, we are excited to have received FDA approval to begin our phase 2 clinical trial to examine the efficacy and safety of psilocybin in treating OCD,” Ceruvia CEO Carey Turnbull said in a company press release. “With few effective

The FDA has approved an investigational new drug application from Ceruvia Lifesciences to conduct a phase 2 clinical trial to determine the safety and efficacy of synthetic psilocybin for the treatment of obsessive-compulsive disorder.
“With positive preliminary results from a Ceruvia-funded pilot phase 2 study taking place at Yale School of Medicine, we are excited to have received FDA approval to begin our phase 2 clinical trial to examine the efficacy and safety of psilocybin in treating OCD,” Ceruvia CEO Carey Turnbull said in a company press release. “With few effective